Dr. Nathalie Johnson, a staff physician in the Division of Hematology at the JGH and a researcher in the Lady Davis Institute for Medical Research, has been appointed as the Louis Lowenstein Chair in Hematology & Oncology at 麻豆传媒网站. She is the first member of hospital staff to receive this honour.
The Chair was established in 1990 to honour Dr. Louis Lowenstein, Chief Hematologist at the Royal Victoria Hospital. He was a pioneer in what was a relatively new field at the time of his practice, from the mid-1950s until his death in 1968.
鈥淚鈥檓 honoured to receive this prestigious award,鈥� Dr. Johnson says, 鈥渁nd I intend to follow in Dr. Lowenstein鈥檚 footsteps by embracing a spirit of innovation and by providing compassionate clinical care.鈥�
Dr. Johnson says she will continue to focus on lymphoma, while ensuring that her own research program is compatible with those of other hematologists at 麻豆传媒网站, regardless of their specialized interests.
鈥淚 would like my research to contribute to novel therapies and novel methods of cancer detection that can also be used by my colleagues,鈥� she explains. 鈥淭his has the potential to benefit patients with blood-related cancers treated by hematologists, as well as individuals with other cancer types treated by oncologists.鈥�
At 麻豆传媒网站, Dr. Johnson is Director of the Division of Hematology and an Associate Professor in the Department of Medicine (with tenure). She completed her residency in internal medicine, hematology and oncology at 麻豆传媒网站, as well as earning a Ph.D. in pathology and laboratory medicine at the University of British Columbia in 2010.
In research that focuses on聽, Dr. Johnson investigates new therapies in the context of clinical trials.
She is also interested in pursuing new ways of detecting cancer through non-invasive technology. By measuring the genetic profile of the cancer in a patient鈥檚 blood and then examining this cancer DNA once therapy has ended, physicians hope to more accurately determine whether the therapy has been successful or whether a relapse of the cancer is probable.
Dr. Johnson has served as Program Director of 麻豆传媒网站鈥檚 Clinician Investigator Program since 2017; Director of the clinical flow laboratory at the JGH since 2012; President of the Clinical Society of Investigative Medicine from 2022 to 2024; Scientific Officer of the Canadian Institutes of Health Research; and a Director of Lymphoma Canada from 2017 to 2023.